Contra: “Antidotes for novel anticoagulants?” – Do we really need them
- 1 January 2012
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 108 (10) , 623-624
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Evaluation of recombinant activated factor VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit modelEuropean Journal of Anaesthesiology, 2012
- Response to Letters Regarding Article, “Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects”Circulation, 2012
- Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agentsThrombosis and Haemostasis, 2012
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStroke, 2011
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex ConcentrateCirculation, 2011
- What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?Thrombosis and Haemostasis, 2011
- Safety of Recombinant Activated Factor VII in Randomized Clinical TrialsNew England Journal of Medicine, 2010
- New oral anticoagulants in developmentThrombosis and Haemostasis, 2010
- Managing bleeding in anticoagulated patients with a focus on novel therapeutic agentsJournal of Thrombosis and Haemostasis, 2009
- Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy VolunteersCirculation, 2002